Controversially, FXR also stimulated the cell growth of renal adenocarcinoma cells by downregulating cyclin-dependent kinase (CDK) inhibitors p16/INK4a and p21/Cip1, but had no effect in the normal renal cell-derived cell line [130]. Here, CDKN2A is linked to papillary renal cell carcinoma.